IDO1 and cancer: Despite these limitations and the failures observed in clinical trials of epacadostat, combination therapies with IDO1 inhibitors and other immuno- or chemotherapeutics for the treatment of cancer still appear to be clinically justified because IDO1 is commonly overactivated in tumors and their microenvironment, both constitutively and induced by the antitumor immune response.